|
Last Updated: Nov 18, 2006 - 12:32:53 PM |
Latest Research
:
Musculoskeletal
:
Muscular Dystrophies
Trichostatin A (TSA) Can Counteract Muscular Dystrophy in Mice
Scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other institutions have demonstrated for the first time that a single drug can rebuild damaged muscle in two strains of mice that develop diseases comparable to two human forms of muscular dystrophy. This advance, which is reported online in Nature Medicine, is the latest from a research collaboration that began several years ago by the teams of Vittorio Sartorelli, M.D., at NIAMS and Pier Lorenzo Puri, M.D., Ph.D., now at Dulbecco Telethon Institute (DTI) in Rome, Italy and The Burnham Institute in La Jolla, Calif.
Oct 5, 2006 - 1:08:00 AM
Latest Research
:
Musculoskeletal
:
Muscular Dystrophies
Valproate effective in adult spinal muscular atrophy (SMA)
An epilepsy drug that has been on the market for decades can ease the symptoms of adult sufferers with a genetic disorder that seriously weakens muscles. Scientists at Washington University School of Medicine in St. Louis retrospectively reviewed results from off-label use of the drug valproate to treat seven adult spinal muscular atrophy (SMA) patients. Clinicians offered the drug to patients on the basis of research conducted elsewhere that showed the drug increased levels of a key protein in cell cultures.
Jun 24, 2006 - 3:00:00 AM
Latest Research
:
Musculoskeletal
:
Muscular Dystrophies
Muscular dystrophy - early cardiac screening shows better outcomes
Cardiac disease, particularly dilated cardiomyopathy and heart failure, is the major cause of mortality in patients with muscular dystrophy.Intervention with ACE inhibitor or beta blocker therapy improves heart size and function.
Oct 30, 2005 - 3:02:00 PM
Latest Research
:
Musculoskeletal
:
Muscular Dystrophies
Gene therapy success for congenital muscular dystrophy (CMD)
Researchers from the University of Pittsburgh report the first study to achieve success with gene therapy for the treatment of congenital muscular dystrophy (CMD) in mice, demonstrating that the formidable scientific challenges that have cast doubt on gene therapy ever being feasible for children with muscular dystrophy can be overcome. Moreover, their results, published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS), indicate that a single treatment can have expansive reach to muscles throughout the body and significantly increase survival.
Aug 16, 2005 - 7:46:00 PM
<< prev
next >>
|
